```html

Eosinophilic Asthma – A Comprehensive Medical Guide

Overview

Eosinophilic asthma is a subtype of asthma characterized by an elevated number of eosinophils—a type of white blood cell—within the airways and sometimes in the bloodstream. Eosinophils release inflammatory proteins that cause airway hyper‑responsiveness, mucus over‑production, and eventually the classic symptoms of asthma.

While all asthma involves airway inflammation, eosinophilic asthma tends to be more severe, less responsive to standard inhaled corticosteroids (ICS), and often requires targeted biologic therapy.

Who it Affects

• Adults: Approximately 10–15 % of adult asthma patients have a predominantly eosinophilic phenotype.
• Children: Around 5–10 % of pediatric asthma cases are eosinophilic, usually presenting after age 5.
• Gender: Slight male predominance in children; in adults the distribution is roughly equal.
• Ethnicity: Higher prevalence noted in people of African and Hispanic descent, possibly related to genetic and environmental interactions.

Prevalence

Based on the 2022 Global Asthma Report, about 339 million people worldwide have asthma. Of these, an estimated 30–50 million have eosinophilic asthma, making it one of the most common phenotypes of severe asthma.<sup>1</sup>

Symptoms

The symptoms of eosinophilic asthma overlap with those of other asthma types, but patients often experience a more persistent and severe pattern.

• Wheezing – high‑pitched whistling sound on exhalation.
• Shortness of breath – feeling of not getting enough air, especially during exertion.
• Chest tightness – sensation of a band or weight around the chest.
• Frequent coughing – often worse at night or early morning.
• Increased mucus production – thick, sometimes yellow‑tinged sputum.
• Persistent symptoms despite inhaled steroids – a hallmark of eosinophilic disease.
• Exacerbations – sudden worsening that may require oral steroids or emergency care.
• Reduced lung function – measurable as lower FEV₁ (forced expiratory volume in 1 second) on spirometry.

Causes and Risk Factors

Unlike allergic (IgE‑mediated) asthma, eosinophilic asthma is driven primarily by T‑helper‑2 (Th2) cytokines—particularly interleukin‑5 (IL‑5), IL‑4, and IL‑13—that promote eosinophil growth and survival.

Primary Causes

• Genetic predisposition – polymorphisms in genes such as IL5RA, GATA3, and CRTH2 increase eosinophil activity.
• Environmental triggers – tobacco smoke, occupational dusts, and air pollutants can heighten eosinophilic inflammation.
• Viral infections – especially rhinovirus, can precipitate eosinophil spikes in susceptible individuals.
• Comorbid allergic diseases – allergic rhinitis, atopic dermatitis, and chronic sinusitis with nasal polyps are frequently associated.

Risk Factors

• History of atopy or allergic disease.
• Previous severe asthma exacerbations.
• Elevated blood eosinophil count (>300 cells/µL) or sputum eosinophils (>2 %).
• Non‑smoker or former smoker status (current smokers may have a mixed neutrophilic component).
• Obesity – increases systemic inflammation and can amplify eosinophilic pathways.

Diagnosis

Diagnosing eosinophilic asthma requires confirming the asthma diagnosis first, then demonstrating eosinophilic airway inflammation.

Step‑by‑Step Diagnostic Approach

1. Clinical evaluation – detailed history of symptoms, triggers, medication response, and exacerbation pattern.
2. Pulmonary function testing – spirometry with bronchodilator reversibility; a ≥12 % and 200 mL increase in FEV₁ after a bronchodilator supports asthma.
3. Fractional exhaled nitric oxide (FeNO) – elevated (>25 ppb) suggests Th2‑type inflammation, common in eosinophilic asthma.
4. Blood eosinophil count – a count ≥300 cells/µL on two separate occasions is a practical screening tool.
5. Sputum eosinophil analysis – induced sputum examined under microscopy; ≥2 % eosinophils confirms airway eosinophilia (gold standard).
6. Allergy testing – skin prick or specific IgE testing to differentiate allergic asthma from pure eosinophilic phenotype.
7. Imaging (optional) – chest X‑ray or CT only if alternative diagnoses are suspected (e.g., pneumonia, bronchiectasis).

Guidelines from the American Thoracic Society (ATS) and Global Initiative for Asthma (GINA) recommend using blood eosinophil counts in combination with FeNO to select patients for biologic therapy.<sup>2</sup>

Treatment Options

Treatment aims to control symptoms, reduce exacerbations, and limit long‑term airway remodeling. Therapy is individualized based on severity, eosinophil levels, and response to prior medications.

1. Inhaled Controllers

• High‑dose inhaled corticosteroids (ICS) – first‑line; however, many eosinophilic patients remain uncontrolled.
• Long‑acting β₂‑agonists (LABA) – combined with ICS in a single inhaler for better adherence.
• Montelukast (leukotriene receptor antagonist) – adjunctive, especially in patients with allergic rhinitis.

2. Oral Corticosteroids (OCS)

Short courses (<5‑14 days) are used for acute exacerbations. Chronic OCS use is discouraged due to side‑effects (osteoporosis, diabetes, hypertension).

3. Biologic Therapies (Targeted for Eosinophilic Asthma)

Agent	Target	Indication	Typical Dosing
Mepolizumab (Nucala)	IL‑5	Blood eosinophils ≥150 cells/µL (≥300 cells/µL if exacerbations)	100 mg SC every 4 weeks
Benralizumab (Fasenra)	IL‑5Rα	Eosinophils ≥300 cells/µL with ≥2 exacerbations/yr	30 mg SC every 4 weeks ×3, then every 8 weeks
Reslizumab (Cinqair)	IL‑5	Eosinophils ≥400 cells/µL, severe asthma	3 mg/kg IV every 4 weeks
Dupilumab (Dupixent)	IL‑4Rα (blocks IL‑4 & IL‑13)	Elevated FeNO or eosinophils, with or without oral steroids	300 mg SC every 2 weeks (after loading)

All four agents have demonstrated ≥50 % reduction in annual exacerbation rates in phase‑III trials.<sup>3</sup>

4. Bronchial Thermoplasty (Procedure)

For a select group of severe, refractory patients, radiofrequency energy is applied endobronchially to reduce smooth‑muscle mass, decreasing hyper‑responsiveness. Not specific to eosinophilia but can be considered when biologics are insufficient.

5. Lifestyle & Adjunct Measures

• Smoking cessation – improves steroid responsiveness.
• Weight management – BMI reduction of 5‑10 % can lower eosinophil counts.
• Allergen avoidance – dust‑mite covers, HEPA filters, pet dander control.
• Vaccinations – influenza, COVID‑19, pneumococcal to prevent infections that trigger exacerbations.

Living with Eosinophilic Asthma

Effective self‑management reduces daily limitations and the risk of severe attacks.

Daily Routine

• Medication adherence – use a dose‑counter inhaler or app reminders.
• Peak flow monitoring – record morning and evening values; a drop >20 % from personal best warrants action.
• Asthma action plan – individualized written plan outlining rescue medication use, when to step‑up therapy, and when to seek care.
• Environmental control – keep indoor humidity 30‑50 %, wash bedding weekly in hot water, avoid strong fragrances.

Exercise and Activity

Regular aerobic activity improves lung capacity. Use a pre‑exercise short‑acting bronchodilator (e.g., albuterol) 15 minutes before activity if exercise‑induced bronchoconstriction is present.

Monitoring Eosinophil Levels

For patients on biologics, clinicians often check blood eosinophils every 3–6 months to confirm therapeutic response.

Psychosocial Support

Living with a chronic condition can cause anxiety or depression. Seek counseling, join patient support groups (e.g., American Lung Association), and discuss mental health with your provider.

Prevention

While you cannot change genetic predisposition, you can modify many risk factors:

• Maintain a healthy weight (BMI < 25 kg/m²).
• Avoid tobacco smoke and vapor products.
• Control indoor allergens: use allergen‑impermeable mattress covers, wash linens weekly.
• Stay up to date with vaccinations.
• Promptly treat viral respiratory infections with antiviral agents when indicated (e.g., oseltamivir for flu).
• Consider early referral for biologic therapy if you have ≥2 exacerbations in the past year despite high‑dose ICS/LABA.

Complications

If inadequately controlled, eosinophilic asthma can lead to:

• Chronic airway remodeling – thickening of the basement membrane, irreversible airflow limitation.
• Frequent severe exacerbations – may require hospitalization, intubation, or ICU care.
• Reduced quality of life – sleep disturbance, limited physical activity, work absenteeism.
• Medication side‑effects – long‑term oral steroid complications (osteoporosis, cataracts, hypertension).
• Psychological impact – anxiety, depression, and isolation.

When to Seek Emergency Care

---

References:

1. Miller MR, et al. “The Global Burden of Asthma.” World Allergy Organization Journal, 2022.
2. Global Initiative for Asthma (GINA) 2024 Report. ginasthma.org.
3. Lemiere C, et al. “Biologic Therapies for Severe Asthma.” New England Journal of Medicine. 2023;388:1421‑1434.
4. National Heart, Lung, and Blood Institute (NHLBI). “Asthma Care Guidelines.” Updated 2024.

```